Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1208027.RAarD_KCirj5IEE0pHtCASf-Mo8Nqa9Ada9_g3iQf6TKo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1208027.RAarD_KCirj5IEE0pHtCASf-Mo8Nqa9Ada9_g3iQf6TKo130_assertion type Assertion NP1208027.RAarD_KCirj5IEE0pHtCASf-Mo8Nqa9Ada9_g3iQf6TKo130_head.
- NP1208027.RAarD_KCirj5IEE0pHtCASf-Mo8Nqa9Ada9_g3iQf6TKo130_assertion description "[An international, multicenter, randomized, open-label trial in 675 previously untreated patients with BRAF(V600E) mutation-positive unresectable or metastatic melanoma allocated 337 patients to receive vemurafenib, 960 mg orally twice daily, and 338 patients to receive dacarbazine, 1,000 mg/m(2) intravenously every 3 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1208027.RAarD_KCirj5IEE0pHtCASf-Mo8Nqa9Ada9_g3iQf6TKo130_provenance.
- NP1208027.RAarD_KCirj5IEE0pHtCASf-Mo8Nqa9Ada9_g3iQf6TKo130_assertion evidence source_evidence_literature NP1208027.RAarD_KCirj5IEE0pHtCASf-Mo8Nqa9Ada9_g3iQf6TKo130_provenance.
- NP1208027.RAarD_KCirj5IEE0pHtCASf-Mo8Nqa9Ada9_g3iQf6TKo130_assertion SIO_000772 25096067 NP1208027.RAarD_KCirj5IEE0pHtCASf-Mo8Nqa9Ada9_g3iQf6TKo130_provenance.
- NP1208027.RAarD_KCirj5IEE0pHtCASf-Mo8Nqa9Ada9_g3iQf6TKo130_assertion wasDerivedFrom befree-2016 NP1208027.RAarD_KCirj5IEE0pHtCASf-Mo8Nqa9Ada9_g3iQf6TKo130_provenance.
- NP1208027.RAarD_KCirj5IEE0pHtCASf-Mo8Nqa9Ada9_g3iQf6TKo130_assertion wasGeneratedBy ECO_0000203 NP1208027.RAarD_KCirj5IEE0pHtCASf-Mo8Nqa9Ada9_g3iQf6TKo130_provenance.